Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $60
Twist Bioscience +4.73% Pre
Twist Bioscience TWST | 42.52 42.52 | +4.73% 0.00% Pre |
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:
TWST) with a Overweight and raises the price target from $45 to $60.